EQS-News: Marinomed Biotech AG: Extraordinary general meeting approves sale of Carragelose division
EQS-News: Marinomed Biotech AG / Key word(s): Strategic Company
Decision/AGM/EGM
Marinomed Biotech AG: Extraordinary general meeting approves sale of
Carragelose division
19.12.2024 / 12:39 CET/CEST
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
Marinomed Biotech AG: Extraordinary general meeting approves sale of
Carragelose division
• Required majority of shareholders vote in favour of the sale of the
Carragelose business unit
• Proceeds from the sale ensure implementation of the restructuring plan
and commercialization of the Marinosolv platform
• Dr. Karl Mahler elected to the Supervisory Board
Korneuburg, Austria, 19. December 2024 – Marinomed Biotech AG (VSE:MARI)
announces that the majority of shareholders approved the sale of the
Carragelose business unit to the French company Unither Pharmaceuticals at
today’s extraordinary general meeting. This approval is an important
prerequisite for the closing of the transaction. In November 2024,
Marinomed signed an agreement on the sale of the Carragelose business,
which provides for upfront and milestone payments of in total up to EUR 20
million. Closing of the deal is still subject to other conditions such as
approval in accordance with the Investment Control Act.
Furthermore, Dr. Karl Mahler has been elected as member of the Supervisory
Board. He holds a doctorate in economics and held several leadership
positions in corporate planning and investor relations, including over 20
years as Head of Investor Relations at Hoffman La Roche. After the
resignation of Dr. Eva Hofstädter-Thalmann and Dr. Ulrich Kinzel, the
Supervisory Board now consists of four members, two women and two men.
All other proposed resolutions of the Management Board and Supervisory
Board, including the creation of new authorized and conditional capital,
were also approved by large majorities.
“The shareholders‘ approval of the sale of the Carragelose business is
essential for the Company’s continued existence. Our strategic focus is
clearly on the commercialization of the Marinosolv products Budesolv and
Tacrosolv and the expansion of the Solv4U service offering. We thank our
shareholders for their support and are working hard to lead the Company to
profitability,” says Andreas Grassauer, CEO of Marinomed.
Further information on the extraordinary general meeting, including the
voting results and the Management Board presentation can be found in the
investors section of the corporate website at:
[1] https://www.marinomed.com/en/investors-esg/annual-general-meeting.
About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline and globally marketed therapeutics. The
Company develops innovative patent-protected products in the therapeutic
areas immunology and virology based on the platform Marinosolv® and the
virus-blocking activity of Carragelose®. The Marinosolv® technology
improves the solubility and bioavailability of hardly soluble compounds
and is used to develop new therapeutics for autoreactive immune disorders.
The virology segment includes Carragelose®-based over-the-counter (OTC)
products to prevent and treat respiratory viral infections that are
partnered in more than 40 countries. The Company is headquartered in
Korneuburg, Austria, and is listed on the Vienna Stock Exchange
(VSE:MARI). For further information, please visit:
[2] https://www.marinomed.com.
For further inquiries contact:
Marinomed Biotech AG
PR & IR: Lucia Ziegler
T: +43 2262 90300 158
E-Mail: [3]pr@marinomed.com
E-Mail: [4]ir@marinomed.com
Disclaimer
This press release contains forward-looking statements, which are based on
current views, expectations and projections of the management of Marinomed
Biotech AG about future events. These forward-looking statements are
subject to risks, uncertainties and assumptions that could cause actual
results, performance or events to differ materially from those described
in, or expressed or implied by, such statements. The current views,
expectations and projections of the management of Marinomed Biotech AG may
be identified by the context of such statements or words such as
“anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
and “target”. Forward-looking statements are only valid as of the date
they are made and Marinomed Biotech AG does not assume any obligation to
update, review or revise any forward-looking statements contained in this
press release whether as a result of new information, future developments
or otherwise. Marinomed, Marinosolv® and Carragelose® are registered
trademarks of Marinomed Biotech AG. These trademarks may be owned or
licensed in select locations only.
══════════════════════════════════════════════════════════════════════════
19.12.2024 CET/CEST This Corporate News was distributed by EQS Group.
www.eqs.com
══════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 2054983
End of News EQS News Service
2054983 19.12.2024 CET/CEST
References
Visible links
1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=cfb52b1a8774a6260659353b50085997&application_id=2054983&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
2. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b364e041c58da1aeff9758a10a9b0152&application_id=2054983&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
3. pr@marinomed.com
4. ir@marinomed.com
OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender